Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $3.00 at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCDFree Report) had its price target reduced by Cantor Fitzgerald from $3.80 to $3.00 in a report released on Wednesday morning, Benzinga reports. They currently have an overweight rating on the stock.

Separately, Needham & Company LLC reiterated a buy rating and issued a $2.50 target price on shares of Lucid Diagnostics in a report on Wednesday.

View Our Latest Stock Analysis on Lucid Diagnostics

Lucid Diagnostics Price Performance

LUCD opened at $0.99 on Wednesday. The business has a fifty day simple moving average of $1.29 and a 200-day simple moving average of $1.34. The firm has a market cap of $44.22 million, a PE ratio of -0.78 and a beta of 1.73. Lucid Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $1.85.

Lucid Diagnostics (NASDAQ:LUCDGet Free Report) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $1.04 million for the quarter. Lucid Diagnostics had a negative return on equity of 8,334.14% and a negative net margin of 2,169.07%. During the same quarter in the previous year, the firm posted ($0.22) EPS. On average, equities research analysts anticipate that Lucid Diagnostics will post -0.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Lucid Diagnostics in the 4th quarter valued at approximately $29,000. LPL Financial LLC lifted its holdings in shares of Lucid Diagnostics by 97.2% during the 3rd quarter. LPL Financial LLC now owns 28,400 shares of the company’s stock worth $33,000 after acquiring an additional 14,000 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at about $87,000. Luminus Management LLC raised its position in Lucid Diagnostics by 2.7% in the second quarter. Luminus Management LLC now owns 878,378 shares of the company’s stock worth $1,221,000 after purchasing an additional 23,078 shares in the last quarter. Finally, BlackRock Inc. raised its position in Lucid Diagnostics by 39.5% in the second quarter. BlackRock Inc. now owns 26,304 shares of the company’s stock worth $37,000 after purchasing an additional 7,448 shares in the last quarter. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test.

Featured Articles

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with's FREE daily email newsletter.